Nina Kjellson

We’re leveraging advances in genetics and precision medicine to develop new therapeutics that target shared, underlying biology in rare and common diseases — bringing meaningful medicines from one to many. With expertise in genetics, drug discovery and data sciences, we seek to identify programs where both biological and technical risk can be minimized to streamline the drug development process and bring forward exceptionally potent and precisely targeted therapeutics for patients.

Proxygen is a Vienna-based startup that develops therapies against cancer and other life-threatening diseases by reprogramming the cellular protein quality control system. We are focused on particular small molecules called “molecular glue degraders” which mediate recruitment of a disease-causing protein to a ubiquitin ligase. Consequently, the target protein is ubiquitinated and directed to the proteasome for degradation. Hence, instead of merely blocking the function of harmful proteins, molecular glue degraders enable their complete, targeted and selective elimination. This outlines a clear avenue towards targeting otherwise undruggable proteins and is therefore seen as one of the most promising innovations of the last decades.

At Rondo Therapeutics we believe that our success as a company starts with building a culture based on teamwork, trust, career growth, and a sense of fun. We develop innovative bispecific antibody therapies, specifically targeting unmet needs in solid tumors. Our bispecific antibodies are designed with broad therapeutic windows, sparing healthy tissue while eradicating tumors. If you are a fearless scientist driven to make new discoveries and you value collaboration, respect, and working in a team environment, then we want to hear from you! Join us in our mission to create novel molecules that bring new hope to cancer patients while advancing your career in a merit-based culture.

Sardona Therapeutics is a preclinical biotechnology company building the leading platform to develop small molecule drugs that target RNA-binding proteins and provide patients with therapy-resistant cancers novel, and potentially best-in-class, treatment options.

Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Companys in-house precision medicine platform, SNÅP, enables the rapid and precise refinement of structural drug design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRAs initial focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions. TYRA is based in Carlsbad, CA.

We’re a creative non-profit empowering girls to change their lives. Started by the Nike Foundation, we are experts in media, tech, brand and international development: a unique mix of skills that we use to solve global problems in a different way. We work across the world in the places where girls are marginalised and vulnerable. We create for young people in ways they love and interact with. And it’s all delivered through the media and mobile tech they use every day – from apps that build skills, to TV dramas that explore vital issues, to magazines written by girls. With our partners, we currently reach 50 million people across Africa and Asia. Our work is helping girls to express themselves, value themselves, and build the relationships they need. Interested in finding out more about our work? Contact us: https://www.girleffect.org/contact-us/

At PACT Pharma, our vision is to create potentially curative T cell therapies for solid cancers that are tailored for each and every patient. We are pioneering non-viral, precision-genome engineered, tumor-specific T-cell therapies for cancer patients because we envision a world where everyone has access to personalized treatment regardless of who they are and where they come from. We currently focus on treating solid tumors. PACT Pharma believes that the only way forward is together, and we look for individuals to join our team who share our values. Teamwork and humility are highly prized. So is speaking with kindness. Be ready to share your ideas, because we create a culture that listens to ideas and isn’t afraid to implement them. If you have a passion for turning ideas into realities and seek a work environment where your colleagues are equally engaged and enthusiastic, you’ll want to join us. If you desire a stimulating fast-paced environment, working with intelligent people who are making an impact in cancer, you will want to join the PACT Pharma team. We are a rapidly expanding, innovative, and collaborative workforce working towards one main goal, eradicating cancer! We are in the San Francisco bay area, the heart of the world’s premier biotechnology research hub. PACT Pharma offers a competitive compensation and benefits package, including participation in the aggressive growth of the company in the form of stock option grants.

The proven software platform for cell and gene therapy supply chain management. From the beginning, Vineti’s founders have understood the challenges that biotech and pharmaceutical innovators face in developing personalized therapies. Vineti’s Personalized Therapy Management (PTM®) platform is the essential enterprise software to drive and scale global personalized therapies, such as cell therapies, gene therapies, and cancer vaccines. PTM® connects the right patient to the right product, on time and on track.

Dauntless Pharmaceuticals, Inc., is a biopharmaceutical company focused on the development of specialty drugs. Our innovative one-asset, one-company model facilitates operational efficiency, drug development speed, and a simplified business development structure, leading to lower costs, shorter timelines and higher returns. Unlike a traditional biotech company which holds numerous assets at various stages of development, and its investors, management, labs, and staff collectively share interest in all company assets, Dauntless uses a one-asset, one-company model where each asset is held in a separate holding company. Dauntless manages the development of each asset and employs expert consultants who specialize in the unique requirements of a given asset. For more information, visit www.dauntlessph.com or e-mail us at info@dauntlessph.com.

Tizona Therapeutics, Inc., is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Founded by MPM Capital and leading scientists from Dana Farber Cancer Institute, the University of Pittsburgh, Johns Hopkins, Memorial Sloan Kettering Cancer Center, and Brigham and Women’s Hospital, Tizona’s therapies are designed to modulate the activity of immunosuppressive cells, thereby activating the body’s ability to fight cancer or preventing the immune system from attacking healthy tissues in autoimmune diseases. Our programs target the cell types and biological mechanisms responsible for immune suppression in the tumor microenvironment and for controlling self-reactivity in autoimmunity. For more information, please email info@tizonatx.com.

Cidara (NASDAQ: CDTX) is developing long-acting therapeutics to improve the standard of care for patients facing serious diseases. The Company’s portfolio is comprised of new approaches aimed at transforming existing treatment and prevention paradigms, first with its lead Phase 3 antifungal candidate, rezafungin, in addition to drug-Fc conjugates (DFCs) targeting viral and oncology diseases from Cidara’s proprietary Cloudbreak® platform. Cidara is headquartered in San Diego, California.

Welltok drives consumer actions that matter. Only Welltok delivers solutions built on a single, secure platform that includes a massive consumer database, machine learning and multi-channel engagement that drives and accounts for targeted actions. As the award-winning consumer activation company, healthcare organizations and others trust Welltok to activate their populations in meaningful ways.

Cebix is developing Ersatta™, a proprietary disease-modifying replacement peptide for the treatment of complications associated with diabetes. Ersatta is a long-acting form of C-peptide that, unlike other products simply directed at symptomatic relief, has the potential to reverse the chronic complications of diabetes. Cebix is evaluating Ersatta in a Phase 2 clinical trial in patients with type 1 diabetes. Type 1 and some type 2 diabetic patients have a C-peptide deficiency, which can cause a reduction in microvascular circulation, resulting in progressive damage to the nerves, retina and kidneys. This damage contributes to the onset of peripheral neuropathy, retinopathy, nephropathy and autonomic neuropathy, all chronic, long-term complications of diabetes. There are currently few treatment options for these complications of diabetes, and there are no approved drugs to treat the microvascular damage.

Eiger is a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious diseases with an unmet need. All five Eiger rare disease programs have been granted FDA breakthrough therapy designation. Eiger's lead clinical programs are focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) infection, the most serious and rapidly progressive form of viral hepatitis. Our HDV platform includes two first-in-class therapies in Phase 3 that target critical host processes involved in viral replication. Eiger's first FDA-approved therapy is Zokinvy for the treatment of Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies - collectively known as progeria. In July 2022, the European Commission also granted Eiger marketing authorization for Zokinvy to treat progeria. For additional information about Eiger and its clinical programs, and for prescribing or safety information, please visit www.eigerbio.com. For our social media and community guidelines, including information on how to report adverse events, please visit www.eigerbio.com/social-media-guidelines/

BIO is the premier biotechnology advocacy organization representing biotech companies, industry leaders, and state biotech associations in the United States and more than 35 countries around the globe. BIO members range from biotech start-ups to some of the world’s largest biopharmaceutical companies – all united by the same goal: to develop medical and scientific breakthroughs that prevent and fight disease, restore health, and improve patients’ lives. BIO also organizes the BIO International Convention and a series of annual conferences that drive partnerships, investment, and progress within the sector. Learn more at bio.org

The mission of the Foundation for the National Institutes of Health (FNIH) is to foster public health through scientific discovery, translational research and the dissemination of research results through specially-configured, high-impact public-private partnerships consistent with the priorities of the National Institutes of Health (NIH). The FNIH is not only involved in large, ambitious initiatives with potentially high impact on the lives of millions of the world’s citizens, but it also supports smaller focused programs in clinical training and ancillary support programs. The FNIH helps to underwrite biomedical initiatives that might not be attractive for private funding alone, or for one reason or another are not appropriate for wholly public funding. The FNIH may take on projects that are particularly risky in terms of the likelihood of success or where companies may be willing to forgo profits because of early stage nature of the program or in the case of some global health initiatives due to the charitable nature of the project. The FNIHs projects tend to be longer-term, operating on a time scale that can be unattractive for private investors. At the same time the foundation is capable of responding quickly and nimbly to funding needs that are immediate and pressing. With the goals of NIH as its guide, the FNIH serves both the public and private sectors, helping them achieve significant breakthroughs in human health in areas of interest that overlap with those of NIH. To learn more about FNIH, its programs and partnership opportunities, or to make a contribution, please visit www.fnih.org

We’re leveraging advances in genetics and precision medicine to develop new therapeutics that target shared, underlying biology in rare and common diseases — bringing meaningful medicines from one to many. With expertise in genetics, drug discovery and data sciences, we seek to identify programs where both biological and technical risk can be minimized to streamline the drug development process and bring forward exceptionally potent and precisely targeted therapeutics for patients.

Proxygen is a Vienna-based startup that develops therapies against cancer and other life-threatening diseases by reprogramming the cellular protein quality control system. We are focused on particular small molecules called “molecular glue degraders” which mediate recruitment of a disease-causing protein to a ubiquitin ligase. Consequently, the target protein is ubiquitinated and directed to the proteasome for degradation. Hence, instead of merely blocking the function of harmful proteins, molecular glue degraders enable their complete, targeted and selective elimination. This outlines a clear avenue towards targeting otherwise undruggable proteins and is therefore seen as one of the most promising innovations of the last decades.

At Rondo Therapeutics we believe that our success as a company starts with building a culture based on teamwork, trust, career growth, and a sense of fun. We develop innovative bispecific antibody therapies, specifically targeting unmet needs in solid tumors. Our bispecific antibodies are designed with broad therapeutic windows, sparing healthy tissue while eradicating tumors. If you are a fearless scientist driven to make new discoveries and you value collaboration, respect, and working in a team environment, then we want to hear from you! Join us in our mission to create novel molecules that bring new hope to cancer patients while advancing your career in a merit-based culture.